SCHEMBL576001

SCHEMBL576001

CCCS(=O)(=O)OS(=O)(=O)CCC

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 0.33
CA2 P00918 3/20 0.33
FAAH O00519 2/20 0.32
MMP2 P08253 1/20 0.31
MMP7 P09237 1/20 0.31
MMP9 P14780 1/20 0.31
MMP14 P50281 1/20 0.31
NPC1 O15118 1/20 0.31
S1PR2 O95136 1/20 0.31
S1PR4 O95977 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
TP53 P04637 1/20 0.31
POLB P06746 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
XBP1 P17861 1/20 0.31
S1PR1 P21453 1/20 0.31
MAPK1 P28482 1/20 0.31
AGTR1 P30556 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18126379 0.91 FAAH (0.39) CA1CA2FAAHNPC1S1PR2
SCHEMBL18126397 0.89 FAAH (0.42) CA1CA2FAAH
SCHEMBL18126340 0.89 FAAH (0.42) CA1CA2FAAH
Acetic Acid SCHEMBL21681579 0.87 FFAR3 (0.35) ALDH1A1LMNAHSD17B10
SCHEMBL6005443 0.85 USP2 (0.33) MMP9ALDH1A1LMNATSHR
Propionic Acid SCHEMBL21681580 0.84 FFAR3 (0.48) ALDH1A1POLBHSD17B10MEN1TSHR
SCHEMBL15868137 0.83 CA2 (0.32) CA2MEN1TSHRKMT2A
SCHEMBL2384895 0.81 HPGD (0.44) CA1CA2FAAHNPC1S1PR2
SCHEMBL4318769 0.80 CA1 (0.33) CA1CA2FAAHMMP2MMP7
SCHEMBL1341402 0.79 FAAH (0.50) CA1CA2FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116942890-A Antibacterial anti-inflammatory thermosensitive hydrogel with function of promoting wound closure and preparation method thereof 西南交通大学 2023-10-27 CN claimed
EP-3190139-B1 METHOD FOR PREPARING AN AROMATIC SULFIDE OR SALT THEREOF IND TECH RES INST (TW) 2019-08-28 EP claimed
US-20170197914-A1 METHOD FOR PREPARING AN AROMATIC SULFIDE OR SALT THEREOF INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2017-07-13 US claimed
EP-3190139-A1 METHOD FOR PREPARING AN AROMATIC SULFIDE OR SALT THEREOF Industrial Technology Research Institute (TW) 2017-07-12 EP claimed
US-6313321-B1 Process for preparing β-hydroxy-γ-butyrolactones and β-(meth)acryloyloxy-γ-butrolactones MITSUBISHI RAYON CO., LTD. (JP) 2001-11-06 US claimed
JP-9157284-A None JP disclosed
CN-110870112-B Lithium ion secondary battery 日本电气株式会社 2024-09-20 CN disclosed
US-20240297344-A1 NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2024-09-05 US disclosed
CN-114174257-B Process for preparing alkanesulphonic acids 巴斯夫欧洲公司 2024-05-14 CN disclosed
CN-116942890-B Antibacterial anti-inflammatory thermosensitive hydrogel with function of promoting wound closure and preparation method thereof 西南交通大学 2024-04-02 CN disclosed
US-11817546-B2 Lithium ion secondary battery NEC CORPORATION (JP) 2023-11-14 US disclosed
CN-116942890-A Antibacterial anti-inflammatory thermosensitive hydrogel with function of promoting wound closure and preparation method thereof 西南交通大学 2023-10-27 CN disclosed
EP-1052258-A1 PROCESS FOR PRODUCING BETA-HYDROXY-GAMMA-BUTYROLACTONE DERIVATIVES AND BETA-(METH)ACRYLOYLOXY-GAMMA-BUTYROLACTONE DERIVATIVES Mitsubishi Rayon Co., Ltd. (JP) 2000-11-15 EP disclosed
EP-1036794-A1 2-ARYL-8-OXODIHYDROPURINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, MEDICINAL COMPOSITIONS CONTAINING THE SAME, AND INTERMEDIATES THEREOF Dainippon Pharmaceutical Co., Ltd. (JP) 2000-09-20 EP disclosed
US-5972946-A NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1999-10-26 US disclosed
US-5786355-A COMPOUNDS FOR TREATMENT OF CANCER, RHEUMATISM, DIABETIC RETINOPATHY OR PSORIASIS TAIHO PHARMACEUTICAL CO., LTD. (JP) 1998-07-28 US disclosed
EP-0826673-A1 ACETAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL COMPOSITION CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1998-03-04 EP disclosed
JP-H09157284-A PRODUCTION OF GLUCOPYRANOSE DERIVATIVE ONO PHARMACEUT CO LTD 1997-06-17 JP disclosed
EP-0767170-A1 NOVEL 4,6-DIARYLPYRIMIDINE DERIVATIVES AND SALTS THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 1997-04-09 EP disclosed
US-4940090-A ACRYLAMIDO-OR SULFONATED VINYL ETHER COMONOMER, ENHANCED OIL RECOVERY MOBIL OIL CORPORATION (US) 1990-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170197914-A1 METHOD FOR PREPARING AN AROMATIC SULFIDE OR SALT THEREOF C1S, ARSA, TST CA1 1781/4885CA2 611/4885FAAH 1521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.